TC Biopharm (Holdings) Plc
TCBP · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $3,845 | $1,979 | $1,979 |
| % Growth | -100% | 94.3% | 0% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $3,845 | $1,979 | $1,979 |
| % Margin | – | 100% | 100% | 100% |
| R&D Expenses | $7,771 | $7,592 | $6,157 | $6,680 |
| G&A Expenses | $6,468 | $8,336 | $3,109 | $2,207 |
| SG&A Expenses | $6,870 | $8,738 | $3,109 | $2,207 |
| Sales & Mktg Exp. | $402 | $402 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $6,913 | $125 | $13,524 | $8,317 |
| Operating Income | -$14,239 | -$12,084 | -$7,287 | -$6,887 |
| % Margin | – | -314.3% | -368.3% | -348.1% |
| Other Income/Exp. Net | $7,244 | $9,050 | -$7,696 | -$291 |
| Pre-Tax Income | -$6,996 | -$3,034 | -$14,983 | -$6,630 |
| Tax Expense | -$1,089 | -$1,720 | -$1,408 | -$1,172 |
| Net Income | -$5,907 | -$1,314 | -$13,576 | -$5,458 |
| % Margin | – | -34.2% | -686.1% | -275.8% |
| EPS | -9.56 | -19.12 | -82,488 | -124 |
| % Growth | 50% | 100% | -66,422.6% | – |
| EPS Diluted | -9.56 | -19.12 | -82,488 | -124 |
| Weighted Avg Shares Out | 618 | 69 | 39 | 56 |
| Weighted Avg Shares Out Dil | 618 | 69 | 39 | 56 |
| Supplemental Information | – | – | – | – |
| Interest Income | $83 | $0 | $0 | $1 |
| Interest Expense | $0 | $6,753 | $3,439 | $292 |
| Depreciation & Amortization | $630 | $762 | $812 | $879 |
| EBITDA | -$13,609 | $4,482 | -$10,733 | -$5,263 |
| % Margin | – | 116.6% | -542.4% | -266% |